ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae

Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00012-20. doi: 10.1128/AAC.00012-20. Print 2020 Apr 21.

Abstract

Plazomicin was tested against 697 recently acquired carbapenem-resistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC50 and MIC90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of >32 mg/liter). Resistance was associated with rmtF-, rmtB-, or armA-encoded 16S rRNA methyltransferases in all except 1 isolate.

Keywords: Klebsiella; antibiotic resistance; carbapenemase; plazomicin.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / pharmacology*
  • Bacterial Proteins / metabolism
  • Carbapenem-Resistant Enterobacteriaceae / drug effects*
  • Drug Resistance, Bacterial / genetics
  • Female
  • Humans
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / genetics
  • Klebsiella pneumoniae / isolation & purification
  • Male
  • Methyltransferases / genetics*
  • Microbial Sensitivity Tests
  • Middle Aged
  • Sisomicin / analogs & derivatives*
  • Sisomicin / pharmacology
  • United States
  • beta-Lactamases / metabolism

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Methyltransferases
  • beta-Lactamases
  • carbapenemase
  • plazomicin
  • Sisomicin